Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 49Neoplasms 36Prostatic Neoplasms 25Carcinoma, Non-Small-Cell Lung 25Polycystic Ovary Syndrome 16Pain 15Keratosis, Actinic 14Leukemia 12Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 10Lung Neoplasms 10Leiomyoma 10Carcinoma, Hepatocellular 10Ovarian Neoplasms 9Neoplasm Metastasis 9Lymphoma, Follicular 9Carcinoma, Renal Cell 9Brain Neoplasms 9Neuroendocrine Tumors 8Arthritis, Rheumatoid 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Kidney Neoplasms 7Head and Neck Neoplasms 7Colonic Neoplasms 7Cancer Pain 7Multiple Myeloma 6Lymphoma 6Liver Neoplasms 6

Interventions

Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Has results × Breakthrough Pain × Clear all
NCT00842829 2012-10-01

Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 4 Terminated
330 enrolled 32 charts

Cancer Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡